Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of CDK8 Inhibitor RVU120 in Combination With Everolimus in Children With Recurrent or Progressive Group 3 or 4 Medulloblastoma

NCT07865130 is registered in ClinicalTrials.gov with Bożenna Dembowska Bagińska as lead sponsor.

NCT NCT07865130
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07865130 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of CDK8 Inhibitor RVU120 in Combination With Everolimus in Children With Recurrent or Progressive Group 3 or 4 Medulloblastoma
Lead sponsor
Bożenna Dembowska Bagińska
Phase
Phase 1
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
June 30, 2033
Enrollment
48 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

medulloblastoma, medulloblastoma recurrent